Πέμπτη 25 Οκτωβρίου 2018

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells.

Conclusion: Current results suggest a potential role of NaPB as a sensitizing agent in NSCLC. PMID: 30349406 [PubMed] (Source: Clinical Pharmacology: Advances and Applications)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2D45Zjp

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.